Your browser doesn't support javascript.
loading
VX-509 (decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation in animal models of autoimmune disease.
Mahajan, Sudipta; Hogan, James K; Shlyakhter, Dina; Oh, Luke; Salituro, Francesco G; Farmer, Luc; Hoock, Thomas C.
Afiliação
  • Mahajan S; Departments of Integrated Biology and Chemistry, Vertex Pharmaceuticals, Boston, Massachusetts (S.M., J.K.H., D.S., L.F., T.C.H.); Sage Therapeutics, Cambridge, Massachusetts (F.G.S.); and Mallinckrodt Pharmaceuticals, Ellicott City, Maryland (L.O.).
  • Hogan JK; Departments of Integrated Biology and Chemistry, Vertex Pharmaceuticals, Boston, Massachusetts (S.M., J.K.H., D.S., L.F., T.C.H.); Sage Therapeutics, Cambridge, Massachusetts (F.G.S.); and Mallinckrodt Pharmaceuticals, Ellicott City, Maryland (L.O.).
  • Shlyakhter D; Departments of Integrated Biology and Chemistry, Vertex Pharmaceuticals, Boston, Massachusetts (S.M., J.K.H., D.S., L.F., T.C.H.); Sage Therapeutics, Cambridge, Massachusetts (F.G.S.); and Mallinckrodt Pharmaceuticals, Ellicott City, Maryland (L.O.).
  • Oh L; Departments of Integrated Biology and Chemistry, Vertex Pharmaceuticals, Boston, Massachusetts (S.M., J.K.H., D.S., L.F., T.C.H.); Sage Therapeutics, Cambridge, Massachusetts (F.G.S.); and Mallinckrodt Pharmaceuticals, Ellicott City, Maryland (L.O.).
  • Salituro FG; Departments of Integrated Biology and Chemistry, Vertex Pharmaceuticals, Boston, Massachusetts (S.M., J.K.H., D.S., L.F., T.C.H.); Sage Therapeutics, Cambridge, Massachusetts (F.G.S.); and Mallinckrodt Pharmaceuticals, Ellicott City, Maryland (L.O.).
  • Farmer L; Departments of Integrated Biology and Chemistry, Vertex Pharmaceuticals, Boston, Massachusetts (S.M., J.K.H., D.S., L.F., T.C.H.); Sage Therapeutics, Cambridge, Massachusetts (F.G.S.); and Mallinckrodt Pharmaceuticals, Ellicott City, Maryland (L.O.).
  • Hoock TC; Departments of Integrated Biology and Chemistry, Vertex Pharmaceuticals, Boston, Massachusetts (S.M., J.K.H., D.S., L.F., T.C.H.); Sage Therapeutics, Cambridge, Massachusetts (F.G.S.); and Mallinckrodt Pharmaceuticals, Ellicott City, Maryland (L.O.) Thomas_hoock@vrtx.com.
J Pharmacol Exp Ther ; 353(2): 405-14, 2015 May.
Article em En | MEDLINE | ID: mdl-25762693
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Valina / Inibidores de Proteínas Quinases / Janus Quinase 3 / Compostos Heterocíclicos com 2 Anéis Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doenças Autoimunes / Valina / Inibidores de Proteínas Quinases / Janus Quinase 3 / Compostos Heterocíclicos com 2 Anéis Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans / Male Idioma: En Ano de publicação: 2015 Tipo de documento: Article